CHATSWORTH, Calif., July 19, 2012 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables and a provider of high-value personalized diagnostics, today announced that it will release its 2012 second quarter financial results after the close of trading on Tuesday, July 31, 2012. IRIS management will also host a conference call and webcast that day at 4:30 P.M. Eastern time to discuss the financial results, as well as provide a general business update.
| Date: | Tuesday, July 31, 2012 |
| Time: | 4:30 PM ET |
To listen via live webcast, please go to the IRIS website (10 min. before conference is scheduled to begin) at: http://www.proiris.com/investors/Webcasts_and_Presentations.php
To participate in the teleconference, please dial (10 min. before conference is scheduled to begin):
| Domestic toll-free: | 877-870-9220 |
| International: | 973-638-3437 |
If you are unable to participate during the live conference call and webcast, the conference call audio cast will be archived and available for replay in the Investors section of the Company's website at http://www.proiris.com for approximately 90 days.
About IRIS International, Inc.
IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with over 3,700 automated urine microscopy systems shipped to more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets, including applications in hematology and body fluids. In addition, the Company's personalized medicine group develops and commercializes the Company's NADiA ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious disease. For more information, please visit www.proiris.com.